Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis

Behnoush, Amir Hossein; Khalaji, Amirmohammad; Bahiraie, Pegah; Alehossein, Parsa; Shobeiri, Parnian; Peisepar, Maral; Cannavo, Alessandro

doi:10.1038/s41440-023-01402-y

Cited by 4 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of these mechanisms, endocan has been considered a potential marker for many pathologies, namely sepsis, lung and kidney diseases, preeclampsia, and chronic heart failure [98]. Regarding cardiovascular disease, endocan can potentially act as a surrogate marker for hypertension [99], coronary artery disease (CAD), coronary slow flow [100], angina, and subclinical atherosclerosis [101,102]. Ziaee et al [75] assessed endocan after a STEMI and UA/NSTEMI and concluded that endocan is independently correlated with MACE, increased thrombolysis in MI (TIMI) risk score and is found in higher levels in STEMI compared to the NSTEMI/UA group.…”

Section: Endocanmentioning

confidence: 99%

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome

Katsioupa,

Kourampi,

Oikonomou

et al. 2023

Life

View full text Add to dashboard Cite

The burden of cardiovascular diseases and the critical role of acute coronary syndrome (ACS) in their progression underscore the need for effective diagnostic and prognostic tools. Biomarkers have emerged as crucial instruments for ACS diagnosis, risk stratification, and prognosis assessment. Among these, high-sensitivity troponin (hs-cTn) has revolutionized ACS diagnosis due to its superior sensitivity and negative predictive value. However, challenges regarding specificity, standardization, and interpretation persist. Beyond troponins, various biomarkers reflecting myocardial injury, neurohormonal activation, inflammation, thrombosis, and other pathways are being explored to refine ACS management. This review article comprehensively explores the landscape of clinically used biomarkers intricately involved in the pathophysiology, diagnosis, and prognosis of ACS (i.e., troponins, creatine kinase MB (CK-MB), B-type natriuretic peptides (BNP), copeptin, C-reactive protein (CRP), interleukin-6 (IL-6), d-dimers, fibrinogen), especially focusing on the prognostic role of natriuretic peptides and of inflammatory indices. Research data on novel biomarkers (i.e., endocan, galectin, soluble suppression of tumorigenicity (sST2), microRNAs (miRNAs), soluble oxidized low-density lipoprotein receptor-1 (sLOX-1), F2 isoprostanes, and growth differentiation factor 15 (GDF-15)) are further analyzed, aiming to shed light on the multiplicity of pathophysiologic mechanisms implicated in the evolution of ACS. By elucidating the complex interplay of these biomarkers in ACS pathophysiology, diagnosis, and outcomes, this review aims to enhance our understanding of the evolving trajectory and advancements in ACS management. However, further research is necessary to establish the clinical utility and integration of these biomarkers into routine practice to improve patient outcomes.

show abstract

Section: Endocanmentioning

confidence: 99%

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome

Katsioupa,

Kourampi,

Oikonomou

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?

Hirooka

2023

Hypertens Res

View full text Add to dashboard Cite

Evaluation and management of hypertensive emergency

Miller,

Hrabec,

Krishnamoorthy

et al. 2024

BMJ

View full text Add to dashboard Cite

Hypertensive emergencies cause substantial morbidity and mortality, particularly when acute organ injury is present. Careful and effective strategies to reduce blood pressure and diminish the effects of pressure-mediated injury are essential. While the selection of specific antihypertensive medications varies little across different forms of hypertensive emergencies, the intensity of blood pressure reduction to the target pressure differs substantially. Treatment hinges on balancing the positive effects of lowering blood pressure with the potential for negative effects of organ hypoperfusion in patients with altered autoregulatory mechanisms. When patients do not have acute organ injury in addition to severe hypertension, they benefit from a conservative, outpatient approach to blood pressure management. In all cases, long term control of blood pressure is paramount to prevent recurrent hypertensive emergencies and improve overall prognosis. This review discusses the current evidence and guidelines on the evaluation and management of hypertensive emergency.

show abstract

Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis

Cited by 4 publications

References 54 publications

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome

How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?

Evaluation and management of hypertensive emergency

Contact Info

Product

Resources

About